65,437 trials
Meningococcal Disease
Primary: Percentage of Subjects With hSBA ≥1:8 — 27; 8; 29; 3 Percentages of subjects
Sepsis
Primary: 28-Day All-Cause Mortality — 26.4; 24.2 percentage of participants — p=0.313
Influenza Vaccination
Primary: Influenza Vaccination — 4; 1; 3; 4 participants — p=<0.05
HIV · HIV Infections
Primary: Combined HIV/STI 12-month Incidence Rates of HIV, Syphilis, Chlamydia, Gonorrhea and Trichomonas Vaginalis. — 65.02; 67.66; 35.02; 54.04 incidence density per 100 person…
Relapsed or Refractory Lymphoproliferative Malignancies · Hodgkin's Lymphoma · Peripheral T-cell Lymphoma
Primary: Objective Responses Assessed by International Workshop Criteria (IWC) — 8; 5; 7 participants
Neurofibroma, Plexiform · Neurofibromatosis Type I
Primary: Median Time to Progression — 10.6; 14.5; 19.2; 13.3 Months
Postpartum Hemorrhage
Primary: Usage — 10 participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment — 0.026; 0.055; -0.073 Liters
Epilepsy
Primary: Number of Participants With Any Rash Event (Including Stevens-Johnson Syndrome [SJS] and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment…
ADHD · Smoking
Primary: Prolonged Abstinence — 25; 28 participants
Multiple Myeloma
Primary: Participants With Dose Limiting Toxicity (DLT) — 0; 0; 0 participants
HIV Infections · Metabolic Syndrome X
Primary: Carotid Intima Media Thickness — -0.02; -0.02; 0.00; 0.03 mm — p=0.37
Breast Cancer
Primary: Cardiac Safety - Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF) — 1; 3; 1 participants
Pain · Peripheral Neuropathy
Primary: Change From Baseline in Mean Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale (NRS) Score at the End of Treatment (15 Weeks) — -1.36; -0.84 units on a scale…
Respiratory Distress Syndrome, Newborn
Primary: Death or Chronic Lung Disease — 76; 68; 62 participants